PRC2 Inactivating Mutations in Cancer are Synthetic Lethal with DNMT1 Targeted Therapy via Enhanced Viral Mimicry
A. J. Patel, S. Warda, J. L. V. Maag, R. Misra, M. A. Miranda-Roman, M. R. Pachai, C. J. Lee, D. Li, N. Wang, G. Bayshtok, Y. Meng, E. W. P. Wong, J. Yan, E. Giff, M. B. Pappalardi, , P. Chi
This paper identifies synthetic lethality between PRC2 inactivation and DNMT1 inhibition in MPNST, showing enhanced cytotoxicity through retrotransposon activation and innate immune signaling.
bioRxiv · May 28, 2022 · PreprintCancer Biology